Genflow Biosciences PLC (LSE:GENF), Europe’s only listed longevity-focused life sciences company, has unveiled its key objectives for 2023.
They include crucial regulatory interactions, the continuation of its Investigational Medicinal Product Dossier (IMPD), expanding scientific collaborations, and exploring new intellectual property opportunities.
The update was provided alongside the company’s prelims, which showed that Genflow exited 2022 with £2.36mln in the bank.
As is to be expected from a business investing heavily in research, the group posted a loss – of £1.33mln for the 12 months that ended December 31.